Table 1 Patient characteristics for all participants at baseline, 3 months and 6 months
Randomisation group | PAP | Mindfulness | Combination |
|---|---|---|---|
Baseline n (%) | |||
Women | 22 (76) | 22 (73) | 20 (69) |
Men | 7 (24) | 8 (27) | 9 (31) |
3 months | |||
Women | 18 (72) | 19 (79) | 17 (65) |
Men | 4 (18) | 5 (21) | 9 (35) |
6 months | |||
Women | 17 (77) | 19 (79) | 15 (63) |
Men | 5 (23) | 5 (21) | 9 (37) |
Age median (range) | |||
Baseline | 54 (42–65) | 53 (41–65) | 54 (43–64) |
Percent of time in sedentary timea mean (SD, range) | |||
Baseline | 66.2 (6.7, 78.2–50.2) | 65.5 (9.2, 80.3–43.7) | 66.7 (8.8, 80.0–47.2) |
3 months follow-up | 66.7 (6.7, 78.3–56.3) | 65.5 (7.5, 78.9–51.3) | 67.5 (8.1, 81.2–51.3) |
6 months follow-up | 65.0 (6.8, 73.6–50.0) | 65.9 (9.4,81.0–36.2) | 64.0 (9.1,78.4–45.6) |
Percent of time in LIPAa mean (SD, range) | |||
Baseline | 30.9 (6.2, 45.5–20.9) | 31.7 (8.2, 50.0–19.0) | 30.3 (8.0, 49.2–18.8) |
3 months follow-up | 31.0 (6.0, 42.6–21.5) | 31.8 (6.9, 47.8–19.9) | 28.6 (7.1,44.5–16.3) |
6 months follow-up | 32.0 (5.8, 43.8–23.1) | 31.6 (9.0, 58.4–17.0) | 32.8 (8.9, 50.7–18.6) |
Percent of time in MVPAamedian (SD, range) | |||
Baseline | 2.6 (0.18, 6.3–0.5) | 2.3 (0.02, 9.1–0.1) | 2.4 (0.02, 9.0–0.2) |
3 months follow-up | 2.4 (0.14, 5.0–0.2) | 1.9. (0.02, 12.7–0.3) | 3.4 (0.03, 11.1–0.1) |
6 months follow-up | 2.6 (0.02, 6.2–0.4) | 1.9 (0.02, 9.0–0.2) | 2.7 (0.02, 9.2–0.3) |
Weight kg median (range) | |||
Baseline | 92.0 (67–121) | 86.8 (57–132) | 81.5 (62–146) |
3 months follow-up | 87.9 (67–111) | 81.2 (56–135) | 83 (62–143) |
6 months follow-up | 91.3 (59–110) | 83.0 (60–139) | 80.2 (60–145) |
BMI kg/m2 median (range) | |||
Baseline | 31.4 (21–43) | 29.9 (22–44) | 28.5 (21–40) |
3 months follow-up | 30.0 (21–42) | 28.6 (22–43) | 28.2 (21–39) |
6 months follow-up | 29.4 (21–42) | 28.6 (23–44) | 27.9 (23–39) |
Total cholesterol mmol/L mean (SD, range) | |||
Baseline | 5.20 (1.05, 7.7–2.9) | 5.63 (0.87, 7.3–4.1) | 5.41 (1.04, 7.4–3.4 ) |
3 months follow-up | 4.99 (1.02, 6.9–3.3) | 5.35 (0.96, 7.1–3.8) | 5.12 (1.00, 7–3.1) |
6 months follow-up | 5.08 (1.23, 7.1–3) | 5.72 (1.09, 7.7–3.6) | 5.08 (1.19, 7.6–2.9) |
Low-density cholesterol mmol/L mean (SD, range) | |||
Baseline | 3.43 (1.04, 5.9–1.3) | 3.80 (0.92, 5.7–2) | 3.66 (0.94, 5.5–2) |
3 months follow-up | 3.15 (0.97, 5.1–1.7) | 3.51 (1.02, 5.8–2) | 3.52 (1.01, 5.3–1.7) |
6 months follow-up | 3.26 (1.14, 5.3–1.5) | 3.83 (1.04, 5.9–1.9) | 3.57 (1.15, 6.3–1.6) |
High-density cholesterol mmol/L median (SD, range) | |||
Baseline | 1.5 (0.54, 3.1–0.9) | 1.4 (0.52, 2.9–0.5) | 1.5 (0.36, 2.4–1.0) |
3 months follow-up | 1.5 (0.56, 2.7–0.9) | 1.5 (0.60, 2.8–0.4) | 1.5 (0.32, 2.1–0.9) |
6 months follow-up | 1.5 (0.55, 2.7–0.9) | 1.4 (0.64, 2.9–0.4) | 1.4 (0.27, 2.3–0.9) |
Triglycerides mmol/L median (SD, range) | |||
Baseline | 1.2 (0.97, 5.1–0.4) | 1.6 (1.14, 5.2–0.5) | 1.4 (0.70, 3.2–0.7) |
3 months follow-up | 1.25 (0.68, 3–0.5) | 1.4 (1.13,4.9–0.8) | 1.5 (0.62, 3.2–0.7) |
6 months follow-up | 1.3 (0.87, 4.1–0.4) | 1.65(1.18, 5.8–0.5) | 1.4 (0.60,3.2–0.7) |
Systolic blood pressure mmHg median (range) | |||
Baseline | 130 (110–160) | 120 (80–160) | 130 (100–155) |
3 months follow-up | 127 (100–150) | 122 (104–165) | 120 (106–145) |
6 months follow-up | 126 (90–160) | 129 (102–150) | 131 (108–160) |
Diastolic blood pressure mmHg median (range) | |||
Baseline | 80 (64–100) | 80 (60–100) | 80 (60–90) |
3 months follow-up | 80 (60–90) | 80 (68–99) | 78(60–90) |
6 months follow-up | 80 (60–100) | 80 (60–100) | 80 (60–100) |
Leisure-time activityb (min = 0, max = 6) median (range) | |||
Baseline | 1 (1–5) | 2 (1–3) | 2 (1–4) |
3 months follow-up | 3 (1–6) | 2 (1–3) | 3 (1–6) |
6 months follow-up | 3 (1–6) | 2 (1–6) | 3 (1–6) |
Daily activityb(min = 0, max = 7) median (range) | |||
Baseline | 3 (1–7) | 3 (1–6) | 4 (1–5) |
3 months follow-up | 5 (2–7) | 3 (1–7) | 5 (1–6) |
6 months follow-up | 5 (3–7) | 4 (1–7) | 5 (1–7) |
ISIb (min = 0, max = 28) median (range) | |||
Baseline | 8 (0–24) | 11 (0–27) | 10 (0–21) |
3 months follow-up | 7 (0–20) | 11 (0–27) | 9 (0–27) |
6 months follow-up | 6 (0–18) | 13 (0–25) | 9 (0–18) |
FFMQb (min = 29, max = 145) mean (SD) | |||
Baseline | 105.5 (80–129) | 105.6 (82–128) | 100.6 (89–114) |
3 months follow-up | 107.6 (90–125) | 103.5 (81–129) | 103.8 (92–117) |
6 months follow-up | 106.8 (85–132) | 102.5 (83–127) | 102.8 (87–116) |
SRHb (min = 1 max = 5) median (range) | |||
Baseline | 3 (1–4) | 3 (2–5) | 3 (2–5) |
3 months follow-up | 3 (1–4) | 3 (2–5) | 4 (2–5) |
6 months follow-up | 4 (1–4) | 4 (2–5) | 4 (2–5) |